Loading the records…
Loading the records…
Its government footprint in one place: federal contracts, private raises, PAC giving and the people tied to it, each row linked to its source.
In plain words
It has one private raise filing with the SEC; the newest states an offering of $3.0M, first sale dated Jun 5, 2026.
Written by fixed rules from the figures on this page. No opinion, no prediction.
No prime contracts of $10M or more matched to this company's name on USAspending.
Prime contracts of $10M or more, largest first, matched on the recipient's whole name as USAspending lists it. Subcontracts and classified work are not included.
No PAC gifts filed under this company's name in the FEC records we hold.
The revolving door and FARA ties are linked to companies by ticker today, so they are not shown for private companies yet. A miss here is not proof of none.
Connections to other companies, executives and members of Congress, from disclosed trades, shared officers and public filings, are part of Pro. See Pro
Records that name this company, newest first: award notices and private raises. Patents are listed below.
USAspending (prime contracts of $10M or more; no subcontracts or classified work; defense contracts can arrive up to 90 days after signing), SAM.gov award notices, SEC Form D, a USPTO patent sample and FEC Schedule A. Records are tied to this company by its whole name, the name without its legal form, or a verified alias, ignoring case; a miss is better than a wrong link. Searched as: BioGene Therapeutics Inc.; BioGene Therapeutics. Nothing here is investment advice.